Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Date:9/24/2009

may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

    CONTACT: Amgen, Thousand Oaks
    Christine Regan: 805-447-5476 (media U.S.)
    Wendy Woods: +41 (0) 41 3692 542 (media Europe)
    Arvind Sood: 805-447-1060 (investors)

'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
4. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
5. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
6. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... , October 31, 2014 ... Inc. (NASDAQ: NSPH ), Isis Pharmaceuticals Inc. ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 30, 2014, the NASDAQ Composite ended at 4,566.14, up ...
(Date:10/31/2014)... British Journal of Urology ... discuss "male orgasmic dysfunction" with their doctor prior to ... symptoms while preserving sexual function     ... a paper in the British Journal of Urology International ... discuss with their doctors the likely impact of treatment ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
... Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or ... September 30, 2009. All figures included herein were prepared ... Mexican pesos. Also, the following consolidated figures show the Company,s ... , 3Q09 Highlights (vs. 3Q08) , During ...
... 26 ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer ... announced that it will release financial results for the third ... Monday, November 2, 2009. The Company will host a ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss ...
Cached Medicine Technology:Genomma Lab Internacional Announces Third Quarter 2009 Results 2Genomma Lab Internacional Announces Third Quarter 2009 Results 3ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 2
(Date:10/31/2014)... life. The last stage, when two daughter cells split ... of cell biology in the Victorian era. For just ... this final step, when the dividing cell creates a ... to this process by those early biologists, cytokinesis, translates ... highly active and organized series of events. Scientists have ...
(Date:10/31/2014)... (PRCHN) at Case Western Reserve University School of ... million in federal grants awarded to improve community ... Disease Control and Prevention (CDC) renewed the PRCHN,s ... funds will support the center,s ongoing efforts in ... interventions that prevent and reduce chronic disease in ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review ... fat loss program ever developed. It promises to provide users ... is no wonder after all that this has become the ... nutrition and workout fat loss program was created by Joel ... to the author of this fat loss system, the method ...
(Date:10/31/2014)... At the start of 2014, numerous ... carbon monoxide poisoning in their homes. Now, as 2015 ... family-owned, Missouri-based heating and cooling company is taking a ... start the home heating season with the assurance that ... Beginning Nov. 1, 2014, E and Q Heating and ...
(Date:10/31/2014)... 2014 Energy Textiles has recently added ... gear is now available online, and Energy Textile is ... Celliant infrared-active athletic gear over compression gear. , ... has been signed for Under Armour to provide team ... eight years. In light of this decision, Energy Textiles ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4
... ( www.PatientAssistance.com ) has released initial survey results on diabetes ... ... Baton Rouge, LA – November 20, 2008 – ... awareness amongst the predominantly uninsured and underinsured visitors of ...
... Amy Rees Anderson, was invited to participate with U.S. Secretary of ... Care. , ... Salt Lake City (Vocus) November 20, ... with U.S. Secretary of Health, Michael Leavitt, in the 2008 National ...
... for the prestigious "Super Dentist" award given to elite dentists in ... top practitioner in the area of Cosmetic Dentistry. , ... ... Austin Smiles was recently nominated as a "Texas Monthly ...
... the frequency of exacerbations in patients with moderate to ... as 35 percent, according to a London-based study. ... macrolide therapy, reducing exacerbation frequency and severity with moderate ... Terence A. R. Seemungal, Ph.D., and Jadwiga Wedzicha, M.D., ...
... NEW YORK Nov. 19, 2008 The American ... and largest non-governmental funder of cancer research and discovery ... Honor, to four Americans who have made outstanding contributions ... will receive their awards at a ceremony during the ...
... says about 40% returned positive results in review of ... Colorectal cancer screening detects 40 percent of cancers and ... Finnish Cancer Registry researchers. , They studied 106,000 people, ... colorectal cancer screening program was in identifying unrecognized disease. ...
Cached Medicine News:Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 2Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 3Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:Scientists honored for contributions to cancer fight 2Health News:Scientists honored for contributions to cancer fight 3Health News:Scientists honored for contributions to cancer fight 4Health News:Scientists honored for contributions to cancer fight 5Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Medicine Products: